GLP1R and type 2 diabetes mellitus: Tirzepatide, a novel dual GIP/GLP-1 receptor agonist, was first approved for improving glycemic control in type 2 diabetes and has shown superior weight-loss effects compared to GLP-1 monotherapy [6,7].